Targeted Oncology - Immunotherapy, Biomarkers, and Cancer …
网页In an interview, Jaime Merchan, MD, explained the background and data from a biomarker analysis of the CLEAR trial in advanced renal cell carcinoma. Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.
News - Targeted Oncology
网页Morgan Bayer. September 15th 2024. The FDA granted IBI363 fast track status for melanoma and approved a ready-to-use subcutaneous bortezomib for MM and MCL. We also cover new data highlighting the efficacy of lenvatinib/pembrolizumab in nccRCC, cost-effectiveness of TKIs for CML, and innovative immunotherapies for T-cell malignancies.
About Us - Targeted Oncology
网页About Us. Through our digital and print media platforms, Targeted Healthcare Communications offers a dedicated website and publication as well as a number of multichannel programs focused on precision medicine in oncology. Targeted Therapies in Oncology is dedicated to providing oncology healthcare …
Targeting AML: The Latest Advances
网页3 天之前 · Patients with acute myeloid leukemia (AML) have benefited from recent advancements in treatment. The advent of drugs targeting specific genetic mutations, such as FLT3, IDH1, IDH2, NPM1, and KMT2A, as well as improved methods for genetic testing have changed the landscape for physicians and the patients they treat.Still, questions remain on how to best optimize treatment protocols.
Adjuvant T-DM1 Continues to Outperform Trastuzumab in HER2 …
网页2023年12月8日 · After 8.4 years follow-up, T-DM1 (ado-trastuzumab emtansine; Kadcycla) led to improved overall survival (OS) and invasive disease-free survival (iDFS) over trastuzumab (Herceptin) in patients with HER2-positive early breast cancer that had residual invasive disease after neoadjuvant therapy, according to findings from the KATHERINE trial that were presented at the 2023 San Antonio Breast ...
IMMUNOTHERAPY - Targeted Oncology
网页July 26th 2024. SenoVax, a novel senolytic immunotherapy for NSCLC, has been submitted as an investigational new drug application to the FDA, initiating a clinical trial to test its efficacy. FDA ODAC Votes Unanimously to Mandate Phase Assessments in NSCLC Perioperative Regimens. By Jordyn Sava. July 25th 2024.
Challenges and Next Steps for Using AI in Cancer Care
网页2 天之前 · Challenges and Next Steps for Using AI in Cancer Care. Anil Parwani, MD, PhD, discusses the challenges and opportunities he has encountered in either implementing or utilizing artificial intelligence technology in the clinical setting. Anil Parwani, MD, PhD, professor of pathology at The Ohio State University Wexner Medical Center, discusses ...
Continuing Osimertinib Treatment After Progression Prolongs Survival ...
网页2019年1月25日 · The investigators said that continuing osimertinib after progression, alone or in conjunction with radiotherapy, may provide prolonged clinical benefit in selected patients. They suggested that further study will be needed, especially given the increasing role for osimertinib in the treatment of EGFR -mutant advanced NSCLC. Reference:
Breast Cancer | Oncology News & Insights | Targeted Oncology
网页4 天之前 · Examining Breast Cancer Recurrence Detection Methods in a Community Oncology Setting. Jordyn Sava. July 12th 2024. In an interview with Targeted Oncology, Ali Duffens, MD, discussed findings from a study which investigated detecting breast cancer recurrence among women treated at Kaiser Permanente Northern California.
Datopotamab Deruxtecan Demonstrates Highly Promising Efficacy …
网页2021年12月7日 · Treatment with datopotamab deruxtecan phase 1 TROPION-PanTumor01 trial (NCT03401385) showed promising activity through overall response rates (ORRs) in patients with advanced or metastatic triple-negative breast cancer (TNBC), according to cohort data presented during the 2021 San Antonio Breast Cancer Symposium (SABCS). 1 Among all patients in the TNBC cohort of the trial (n = 44), the ORR by ...
跳至内容